Skip to main content
SYRS logo

Syros Pharmaceuticals, Inc. (SYRS) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.0001 $0.00 (0.00%)
Vol: 904| 52-wk range: $0.0001 – $0.02
Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Syros Pharmaceuticals, Inc. (SYRS) trades at $0.0001. Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for cancer and monogenic diseases through gene control. Sector: Healthcare.

Price as of · Last analyzed: May 4, 2026
Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for cancer and monogenic diseases through gene control. Their pipeline includes Tamibarotene, SY-2101, and SY-5609, targeting myelodysplastic syndrome, acute promyelocytic leukemia, and advanced solid tumors, respectively.

Analyst Coverage for SYRS: SYRS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • NVO · Novo Nordisk A/S · 87 /100
  • VRTX · Vertex Pharmaceuticals Incorporated · 90 /100
  • REGN · Regeneron Pharmaceuticals, Inc. · 95 /100

See all scored stocks →

Syros Pharmaceuticals, Inc. (SYRS) Healthcare & Pipeline Overview

CEOJames E. Bradner
Employees68
HeadquartersCambridge, MA, US
IPO Year2016

Syros Pharmaceuticals, Inc., a clinical-stage biotechnology company, is dedicated to pioneering gene control medicines for cancer and monogenic diseases. Their pipeline features Tamibarotene, SY-2101, and SY-5609, addressing significant unmet needs in myelodysplastic syndrome, acute promyelocytic leukemia, and advanced solid tumors, positioning them within a competitive biotech landscape.

Data Provenance | Financial Data Quantitative Analysis Analysis: May 4, 2026

What Is the Investment Thesis for SYRS?

AI-written as of May 4, 2026 — figures and tone reflect the data available then, not today's score.

Syros Pharmaceuticals presents a high-risk, high-reward investment profile typical of clinical-stage biotech companies. The primary value driver is the successful development and commercialization of Tamibarotene, particularly for the treatment of myelodysplastic syndrome (MDS). Positive Phase III trial results and subsequent regulatory approval could significantly increase the company's valuation. The advancement of SY-2101 and SY-5609 through clinical trials represents additional upside potential. However, the company's negative profit margin of -1656.3% underscores its reliance on external funding and the inherent risks associated with drug development, including clinical trial failures and regulatory hurdles. The company's gross margin is 77.3%.

Based on FMP financials and quantitative analysis

SYRS Key Highlights

AI-written as of May 4, 2026 — figures and tone reflect the data available then, not today's score.

Syros Pharmaceuticals is focused on gene control medicines for cancer and monogenic diseases.

  • Tamibarotene, a selective retinoic acid receptor alpha agonist, is in Phase III clinical trial for myelodysplastic syndrome.
  • SY-2101, a novel oral form of arsenic trioxide, is being developed for acute promyelocytic leukemia.
  • SY-5609, a cyclin-dependent kinase 7 inhibitor, is in a Phase I clinical trial for advanced solid tumors.
  • The company has a gross margin of 77.3%.

Who Are SYRS's Competitors?

SYRS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
NVO Novo Nordisk A/S $38.87 -1.42% $171B 87 5-pillar
VRTX Vertex Pharmaceuticals Incorporated $536.45 +0.42% $136B 90 5-pillar
REGN Regeneron Pharmaceuticals, Inc. $945.53 -1.28% $97.8B 95 5-pillar
ARGX argenx SE $942.04 +0.08% $59.2B 96 5-pillar
RPRX Royalty Pharma plc $68.67 -0.01% $39.5B 73 5-pillar
GMAB Genmab A/S $50.97 -1.91% $31.4B 72 5-pillar
UTHR United Therapeutics Corporation $577.34 -1.16% $24.6B 97 5-pillar
INCY Incyte Corporation $117.80 -1.08% $24.0B 91 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SYRS's Key Strengths?

Proprietary gene control technology platform.

  • Clinical-stage pipeline with multiple drug candidates.
  • Strategic collaborations with Incyte and TMRC.
  • Experienced management team.

What Are SYRS's Weaknesses?

High reliance on clinical trial success.

  • Significant financial risk due to negative profit margin.
  • Limited commercialization experience.
  • Dependence on external funding.

What Are the Key Risks for SYRS?

Financial-distress signal — its Altman Z-Score of -15.54 sits in the distress zone (elevated bankruptcy risk).

  • Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
  • Clinical trial failures for Tamibarotene, SY-2101, or SY-5609.
  • Regulatory hurdles and delays in obtaining drug approvals.
  • Competition from established pharmaceutical companies and other biotechnology firms.
  • Dependence on external funding to support research and development activities.
  • Risks associated with trading on the OTC market, including limited liquidity and disclosure.

What Are SYRS's Competitive Advantages?

  • Proprietary gene control technology.
  • Clinical-stage pipeline of drug candidates.
  • Intellectual property protection for its drug candidates.
  • Strategic collaborations with leading pharmaceutical companies.

What Does SYRS Do?

Syros Pharmaceuticals, Inc., founded in 2011 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on developing treatments for cancer and monogenic diseases. The company aims to control genes to treat diseases. Syros's lead product candidate is Tamibarotene, a selective retinoic acid receptor alpha agonist, currently in Phase III clinical trial for a genomically defined subset of patients with myelodysplastic syndrome (MDS) and Phase II clinical trial for patients with acute myeloid leukemia (AML). Another key asset is SY-2101, a novel oral form of arsenic trioxide, intended for treating patients with acute promyelocytic leukemia (APL). Additionally, SY-5609, a cyclin-dependent kinase 7 (CDK7) inhibitor, is in a Phase I clinical trial for patients with select advanced solid tumors. Syros has also established collaborations to expand its research and development efforts. This includes a target discovery, research collaboration, and option agreement with Incyte Corporation, focused on identifying therapeutic targets for myeloproliferative neoplasms. Furthermore, the company has a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. Formerly known as LS22, Inc., Syros Pharmaceuticals, Inc. changed its name in August 2012, marking a new chapter in its commitment to gene control medicines.

What Products and Services Does SYRS Offer?

  • Develop gene control medicines for cancer and monogenic diseases.
  • Conduct clinical trials for Tamibarotene in myelodysplastic syndrome and acute myeloid leukemia.
  • Develop SY-2101, an oral form of arsenic trioxide, for acute promyelocytic leukemia.
  • Develop SY-5609, a CDK7 inhibitor, for advanced solid tumors.
  • Collaborate with Incyte Corporation to identify therapeutic targets for myeloproliferative neoplasms.
  • License tamibarotene to TMRC Co. Ltd. for development and commercialization.

How Does SYRS Make Money?

  • Develop and commercialize proprietary drug candidates.
  • Generate revenue through product sales upon regulatory approval.
  • Establish collaborations and licensing agreements to expand research and development efforts.
  • Receive milestone payments and royalties from partners.

What Industry Does SYRS Operate In?

Syros Pharmaceuticals operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory scrutiny, and significant financial risk. The market for cancer and monogenic disease treatments is substantial and growing, driven by an aging population and advancements in genomic medicine. Competition is fierce, with numerous companies pursuing similar therapeutic targets. Syros differentiates itself through its focus on gene control medicines and its pipeline of clinical-stage assets. The company's success depends on its ability to navigate the complex regulatory landscape and secure funding to advance its programs.

Who Are SYRS's Key Customers?

  • Patients with cancer and monogenic diseases.
  • Healthcare providers who prescribe and administer Syros's therapies.
  • Pharmaceutical companies through collaborations and licensing agreements.
  • Research institutions involved in clinical trials and drug development.
Model self-rating on this text: 66% (not a measure of the evidence) Updated: May 4, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● No usable price
  • ● No filing on record
  • ● No analyst coverage
F-Score 0/9

Financial Health

Syros Pharmaceuticals, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.54 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -97.9%, showing how much profit it generates from its asset base. A current ratio of 3.95 indicates the company holds enough short-term assets to cover its near-term obligations.

Company Profile

Syros Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO James E. Bradner. SYRS has traded publicly since 2016.

4/8 beats

Earnings Track Record

Syros Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 0.6% above estimates on average.

FY2026 est

Forward Outlook

Wall Street analysts project Syros Pharmaceuticals, Inc. revenue of about $1.7M for fiscal 2026, with EPS near $-0.60.

SYRS Latest News

No recent news available for SYRS.

SYRS Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SYRS.

Price Targets

Wall Street price target analysis for SYRS.

SYRS MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SYRS; grades run from A+ (80-100) to F (below 30).

Leadership: James E. Bradner

Unknown

Information about James E. Therefore, I am unable to provide details regarding his career history, education, previous roles, or credentials. Without access to this information, I cannot accurately portray his professional journey and qualifications.

Track Record: Information about James E. Bradner's track record is not available in the provided data. Therefore, I am unable to provide details regarding his key achievements, strategic decisions, or company milestones under his leadership. Without access to this information, I cannot accurately portray his professional accomplishments and impact on the company.

SYRS OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that Syros Pharmaceuticals may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Trading on the OTC Other tier often implies a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ, due to less stringent listing requirements and potentially lower liquidity.

  • OTC Tier: OTC Other
Liquidity: Liquidity on the OTC Other tier is typically very low, with wide bid-ask spreads and limited trading volume. This can make it difficult for investors to buy or sell shares without significantly impacting the price. The lack of liquidity increases the risk of price volatility and makes it challenging to execute large trades. Investors should be prepared for potential delays in order execution and the possibility of significant price fluctuations.
OTC Risk Factors:
  • Limited financial disclosure increases information asymmetry.
  • Low trading volume and liquidity can lead to price volatility.
  • Higher risk of fraud or manipulation compared to listed exchanges.
  • OTC Other tier companies may have difficulty raising capital.
  • Delays in trade execution due to low volume.
Due Diligence Checklist:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the background and experience of the management team.
  • Assess the company's business model and competitive landscape.
  • Review the company's capitalization structure and ownership.
  • Consult with a financial advisor to understand the risks involved.
  • Check for any regulatory actions or legal proceedings against the company.
  • Confirm the company's contact information and physical address.
Legitimacy Signals:
  • Established partnerships or collaborations with reputable companies.
  • Experienced management team with a track record of success.
  • Clear and transparent communication with investors.
  • Independent audits of financial statements (if available).
  • Active engagement with the investment community.

Syros Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

What do analysts say about SYRS stock?

Analyst coverage of Syros Pharmaceuticals, Inc. is not available in the provided data. Therefore, I am unable to provide a summary of analyst consensus, key valuation metrics, or growth considerations.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based solely on the provided source data.
  • OTC market data may be limited or outdated.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives